56F Stock Overview
A clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
EXACT Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.64 |
| 52 Week High | kr1.63 |
| 52 Week Low | kr0.46 |
| Beta | 0.13 |
| 11 Month Change | 8.47% |
| 3 Month Change | 28.00% |
| 1 Year Change | -36.00% |
| 33 Year Change | -71.17% |
| 5 Year Change | n/a |
| Change since IPO | -73.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 56F | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.9% | 0.04% | -3.5% |
| 1Y | -36.0% | -22.3% | 1.7% |
Return vs Industry: 56F underperformed the German Biotechs industry which returned -22.3% over the past year.
Return vs Market: 56F underperformed the German Market which returned 1.7% over the past year.
Price Volatility
| 56F volatility | |
|---|---|
| 56F Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 56F's share price has been volatile over the past 3 months.
Volatility Over Time: 56F's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 12 | Per Walday | exact-tx.com |
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. The company’s ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy.
EXACT Therapeutics AS Fundamentals Summary
| 56F fundamental statistics | |
|---|---|
| Market cap | €21.02m |
| Earnings (TTM) | -€4.28m |
| Revenue (TTM) | €394.70 |
Over9,999x
P/S Ratio-4.9x
P/E RatioIs 56F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 56F income statement (TTM) | |
|---|---|
| Revenue | kr4.46k |
| Cost of Revenue | kr0 |
| Gross Profit | kr4.46k |
| Other Expenses | kr48.34m |
| Earnings | -kr48.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,084,201.23% |
| Debt/Equity Ratio | 0% |
How did 56F perform over the long term?
See historical performance and comparison